Showing results (211-220 of 221) with videos related to
Sort By:
Pageof 23
Inflammatory Bowel Diseases|February 8, 2013
Quality indicators for inflammatory bowel disease: development of process and outcome measuresGil Y Melmed, Corey Allan Siegel, Brennan M Spiegel, et al.Gastroenterology|February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial ResultsGeert R D'Haens, William J Sandborn, Edward V Loftus, et al.The American Journal of Gastroenterology|November 4, 2010
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Geert R D'Haens, Remo Panaccione, Peter D R Higgins, et al.Pharmaceutics|April 26, 2025
The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience ProgramStephen B Hanauer, Esther A Torres, Patricia Aragon-Han, et al.The American Journal of Gastroenterology|March 18, 2006
Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locusJean-Paul Achkar, Themistocles Dassopoulos, Mark S Silverberg, et al.The American Journal of Gastroenterology|May 16, 2006
Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohortGeoffrey C Nguyen, Esther A Torres, Miguel Regueiro, et al.The New England Journal of Medicine|December 14, 2016
Ustekinumab as Induction and Maintenance Therapy for Crohn's DiseaseBrian G Feagan, William J Sandborn, Christopher Gasink, et al.Gastroenterology|May 24, 2024
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)Stephen B Hanauer, Bruce E Sands, Stefan Schreiber, et al.Journal of Crohn'S & Colitis|April 17, 2025
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)Jean-Frederic Colombel, William J Sandborn, Stefan Schreiber, et al.Gastroenterology|May 30, 2025
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel DiseaseJurij Hanžel, Virginia Solitano, Sudheer Kumar Vuyyuru, et al.Pageof 23